- Home
- APRE vs CYCN Comparison
APRE vs CYCN Comparison
Compare APRE & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- CYCN
- Stock Information
- Founded
- APRE 2006
- CYCN 2018
- Country
- APRE United States
- CYCN United States
- Employees
- APRE N/A
- CYCN N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- CYCN Health Care
- Exchange
- APRE Nasdaq
- CYCN Nasdaq
- Market Cap
- APRE 9.4M
- CYCN 8.0M
- IPO Year
- APRE 2019
- CYCN N/A
- Fundamental
- Price
- APRE $1.55
- CYCN $2.22
- Analyst Decision
- APRE Strong Buy
- CYCN
- Analyst Count
- APRE 1
- CYCN 0
- Target Price
- APRE $20.00
- CYCN N/A
- AVG Volume (30 Days)
- APRE 33.0K
- CYCN 23.2K
- Earning Date
- APRE 11-06-2025
- CYCN 08-05-2025
- Dividend Yield
- APRE N/A
- CYCN N/A
- EPS Growth
- APRE N/A
- CYCN N/A
- EPS
- APRE N/A
- CYCN N/A
- Revenue
- APRE $841,012.00
- CYCN $2,174,000.00
- Revenue This Year
- APRE N/A
- CYCN N/A
- Revenue Next Year
- APRE N/A
- CYCN N/A
- P/E Ratio
- APRE N/A
- CYCN N/A
- Revenue Growth
- APRE N/A
- CYCN N/A
- 52 Week Low
- APRE $1.41
- CYCN $1.27
- 52 Week High
- APRE $5.01
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- APRE 42.03
- CYCN 38.54
- Support Level
- APRE $1.49
- CYCN $2.45
- Resistance Level
- APRE $1.65
- CYCN $2.59
- Average True Range (ATR)
- APRE 0.08
- CYCN 0.23
- MACD
- APRE -0.01
- CYCN 0.00
- Stochastic Oscillator
- APRE 23.08
- CYCN 7.47
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.